The shadow of generic competition has repeatedly loomed above copyright’s famous drug, PDE5 Inhibitor, sparking questions about the prospects of connected medicinal portfolios. While initial times saw significant profits, the patent end has allowed the way for discounted copies, possibly lowering earnings and posing a genuine danger for stakehold